Tag Archives: BIO CEO & Investor Conference

Fireside Chats with Five CEOs Featured at Day Two of the BIO CEO & Investor Conference

DSC_9222

Fireside Chat with John F. Milligan, PhD, President & COO, Gilead Sciences The first fireside chat of the BIO CEO and Investor Conference featured John F. Milligan, Ph.D. President & COO of Gilead Sciences.  In a session moderated by Barclays analyst Geoff Meacham, Dr. Milligan was optimistic that sales of Gilead’s Hepatitis C treatments would see expanded sales volumes as more providers become comfortable with the regimens and treating HCV patients, according to Milligan. He Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Session Recap: “Trust Your Gut” – Therapeutic Opportunities from the Microbiome

Kaylee_dna_115x76

Tuesday at the BIO CEO & Investor Conference kicked off with a Therapeutic Workshop titled, “Trust Your Gut” – Therapeutic Opportunities from the Microbiome. The panel was moderated by Mark Breidenbach, PhD, Equity Research Group, H.C. Wainwright & Co. The panelists were: Martin J. Blaser, MD, Muriel and George Singer Professor of Medicine, Professor of Microbiology, Director, Human Microbiome Program, New York University Langone Medical Center Karim Dabbagh, PhD, Chief Scientific Officer, Second Genome Michael Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Ten Years of Therapeutic Venture Capital

vc-blog

What therapeutic areas have received the most funding in private drug companies over the last decade? How much of this has been for new drugs vs drug delivery? How much into biologics vs small molecules? This week, we released a first-of-its-kind, comprehensive report on venture capital trends covering 2004-2013. To investigate investor trends in specific therapeutic areas and level of innovation, we analyzed data from four venture capital databases to create the broadest, most comprehensive Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Session Recap: Digital Health—Early Successes for Investors and Biotech R&D Productivity

shutterstock_27160801

Digital health has the potential to improve the life science industry by combining traditional and novel medicines with digital technologies, enabling the life sciences to become more patient-centered as well as accelerating product discovery. There is growing interest in digital health among investors as new data and technologies become available that fill unmet needs in the marketplace. At the 17th Annual BIO CEO & Investor Conference, a panel of digital health experts came together to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Producing “21st Century Cures” – 2015 U.S. Legislative Outlook with Chairman Upton and Rep. DeGette

21st Century Cures Act

BIO President & CEO Jim Greenwood today sat down with Energy & Commerce Committee Chairman Fred Upton (R-MI) and Congresswoman Diana DeGette (D-CO) for a lively and in-depth discussion of the 21st Century Cures Initiative, a comprehensive effort to accelerate the discovery, development and delivery of new drugs and therapies. The conversation was a great way to kick off the opening plenary of the 17th BIO CEO & Investor Conference. This year’s conference, as Greenwood noted, has a Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,